| Schedule Of Segment Reporting Information |
| |
|
Consumer
Products Segment |
|
|
Specialty
Pharmaceutical
Segment |
|
|
Consolidated
Totals |
|
| Years Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| December 31, 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
11,060,636 |
|
|
$ |
– |
|
|
$ |
11,060,636 |
|
| Gross profit |
|
|
6,997,635 |
|
|
|
– |
|
|
|
6,997,635 |
|
| Gain on collection of related party notes receivable |
|
|
379,486 |
|
|
|
– |
|
|
|
379,486 |
|
| Gain on change in derivative liability |
|
|
147,200 |
|
|
|
– |
|
|
|
147,200 |
|
| Impairment of inventory |
|
|
(3,562,459 |
) |
|
|
– |
|
|
|
(3,562,459 |
) |
| Impairment of PhytoSPHERE goodwill and intangible
assets |
|
|
(2,746,512 |
) |
|
|
– |
|
|
|
(2,746,512 |
) |
| Selling, general and administrative |
|
|
(12,741,211 |
) |
|
|
(388,739 |
) |
|
|
(13,129,950 |
) |
| Research and development |
|
|
(834,963 |
) |
|
|
(324,046 |
) |
|
|
(1,159,009 |
) |
| Operating (loss) income |
|
$ |
(12,360,824 |
) |
|
$ |
(712,785 |
) |
|
$ |
(13,073,609 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| December 31, 2015: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
11,529,402 |
|
|
$ |
– |
|
|
$ |
11,529,402 |
|
| Gross profit |
|
|
6,730,984 |
|
|
|
– |
|
|
|
6,730,984 |
|
| Litigation settlement income |
|
|
756,714 |
|
|
|
– |
|
|
|
756,714 |
|
| Selling, general and administrative |
|
|
(17,377,282 |
) |
|
|
– |
|
|
|
(17,377,282 |
) |
| Research and development |
|
|
(1,320,003 |
) |
|
|
– |
|
|
|
(1,320,003 |
) |
| Operating (loss) income |
|
$ |
(11,209,587 |
) |
|
$ |
– |
|
|
$ |
(11,209,587 |
) |
|